title: Tamsulosin: an overview.
abstract: This article reviews the contemporary literature related to tamsulosin, which is now the most widely used alpha antagonist in treating benign prostatic hyperplasia. The primary emphasis of this article is on the clinical data that exist related to this agent. Currently, there are no adequate studies that effectively compare existing agents for the treatment of benign prostatic hyperplasia using a randomised, placebo-controlled design with adequate numbers and this needs to be addressed in future studies.
authors.affiliation: Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK. c.r.chapple@shef.ac.uk
authors.forename: Christopher
authors.initials: C
authors.lastname: Chapple
authors.forename: Karl-Erik
authors.initials: KE
authors.lastname: Andersson
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005060:Europe; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin; D016896:Treatment Outcome; D014481:United States
chemical_list: D000317:Adrenergic alpha-Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin